This study is testing a drug called Valganciclovir along with standard care for people with breast cancer that has spread to the brain (brain metastases) and who also have a cytomegalovirus (CMV) infection. Valganciclovir works by stopping the CMV virus from growing. The study aims to see how well this treatment shrinks the brain tumors (Objective Response Rate) after 6 weeks. You might be able to join if you are 18 or older, have metastatic breast cancer in your brain that is getting worse, and have signs of a CMV infection in your blood. The study plans to enroll 28 participants.

Study design

This is a Phase II interventional study with an initial safety lead-in, planning to enroll 28 participants. It will evaluate the effects of Valganciclovir and standard-of-care treatment.

What's involved

Participants will receive oral Valganciclovir twice a day for two weeks. You will have weekly lab tests to check for viral clearance, blood cell counts, and electrolyte levels.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, Objective Response Rate, is measured at 6 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.